Personalized medicine — stages of concept formation and ways of its practical implementation
Abstract
Personalized medicine is a new paradigm in healthcare, based on understanding of the importance of an individual treatment approach and based on knowledge about genomic predictors and post-genomic markers of various diseases. Complementing the concept of evidence-based medicine, personalized medicine opens up new opportunities for doctors and researchers to treat patients more effectivel. At the same time it raises many medical, ethical and legal issues.
This article describes the current state of the problem with specific examples of the implementation of this approach by the leading institutions of the Russian Federation (including the Endocrinology Research Center).
About the Authors
N. G. Mokrysheva
National Medical Research Center for Endocrinology
Russian Federation
Russian Federation
Mokrysheva Natalia G., PhD, Corresponding Member of the Russian Academy of Sciences, Director
Moscow
G. A. Mel’nichenko
National Medical Research Center for Endocrinology
Russian Federation
Russian Federation
Melnichenko Galina A., PhD, Academician of the Russian Academy of Sciences, Medical Doctor, Deputy Director
st. Dmitry Ulyanov, 11, Moscow, Russia, 117292
References
1. Dedov II, Tyul’pakov AN, Chekhonin VP, et al. Personalized medicine: State-of-the-art and prospects. Annals of the Russian Academy of Medical Science. 2012;67(12):4–11. DOI: 10.15690/vramn.v67i12.474. In Russian
2. Dedov II, SHestakova MV, Maksimova MA. Federal target program “Diabetes mellitus” (guidelines). M.: Izdatel’stvo Media Sfera; 2002. 88 p. In Russian
3. Dedov II, Shestakova MV, Mayorov AYu. Standards of specialized diabetes care (9th Edition). Diabetes Mellitus. 2019;22(1S1):1–144. DOI: 10.14341/DM221S1. In Russian
4. Sackett DL, Rosenberg WM, Gray JA, et al. Evidence based medicine: what it is and what it isn’t. BMJ. 1996;312(7023):71–72. DOI: 10.1136/bmj.312.7023.71.
5. Shlyahto EV. Translational medicine. SPb.: Severo-Zapadnyj federal’nyj medicinskij issledovatel’skij centr im. V. A. Almazova, 2010. 415 p. In Russian
6. Mediouni M, Schlatterer DR, Madry H, et al. A review of translational medicine. The future paradigm: how can we connect the orthopedic dots better? Curr Med Res Opin. 2018;34(7):1217–1229. DOI: 10.1080/03007995.2017.1385450.
7. Sychev DA. Stages of development and implementation of personalized medicine technologies in clinical practice. World Journal of Personalized Medicine. 2017;1(1):1–4. In Russian
8. Zastrozhin MS, Sychev DA, Grishina EA, et al. Pharmacodynamic gene polymorphism and adverse drug reactionsthen applying antipsychotic drugs. World Journal of Personalized Medicine. 2017;1(1):5-12. DOI: 10.14341/WJPM9265. In Russian
9. Savelyeva MI, Panchenko YuS, Urvantseva IA, et al. Perspectives of pharmacogenetics approach to personalized tamoxifen therapy. World Journal of Personalized Medicine. 2017;1(1):27–35. DOI: 10.14341/
10. WJPM9274. In Russian
11. Kulikova KS, Vasiliev EV, Petrov VM, et al. Autosomal dominant hypophosphataemic rickets is associated with mutations in FGF23 gene in child from Russia. World Journal of Personalized Medicine. 2018;2(1):5–9. DOI: 10.14341/pm9661. In Russian
12. Voronkova IA, Eremkina AK, Krupinova YA, et al. Neuroendocrine markers in parathyroid tumors. Arkh Patol. 2020;82(6):70–78. DOI: 10.17116/patol20208206170.
13. Eremkina A, Krupinova J, Dobreva E, et al. Denosumab for management of severe hypercalcemia in primary hyperparathyroidism. Endocr Connect. 2020;9(10):1019–1027. DOI: 10.1530/EC-20-0380.
14. Gorbacheva AM, Eremkina AK, Mokrysheva NG. Hereditary syndromal and nonsyndromal forms of primary hyperparathyroidism. Probl Endokrinol (Mosk). 2020;66(1):23–34. DOI: 10.14341/probl10357.
15. Gronskaia G, Melnichenko L, Rozhinskaya T, et al. A registry for patients with chronic hypoparathyroidism in Russian adults. Endocr Connect. 2020;9(7):627–636. DOI: 10.1530/EC-20-0219.
16. Belaya Z, Khandaeva P, Nonn L, et al. Circulating Plasma microRNA to Differentiate Cushing’s Disease From Ectopic ACTH Syndrome. Front Endocrinol (Lausanne). 2020;11:331. DOI: 10.3389/fendo.2020.00331.
17. Lutsenko AS, Belaya ZE, Przhiyalkovskaya EG, et al. Expression of plasma microRNA in patients with acromegaly. Probl Endokrinol (Mosk). 2019;65(5):311–318. DOI: 10.14341/probl10263.
18. Mamedova EO, Dimitrova DA, Belaya ZE, et al. The role of non-coding RNAs in the pathogenesis of multiple endocrine neoplasia syndrome type 1. Probl Endokrinol (Mosk). 2020;66(2):4–12. DOI: 10.14341/probl12413.
19. Lapshina AM, Khandaeva PM, Belaya ZE, et al. Role of microRNA in oncogenesis of pituitary tumors and their practical significance. Ter Arkh. 2016;88(8):115–120. DOI: 10.17116/terarkh2016888115-120.
20. Nadezhdina EY, Rebrova OY, Grigoriev AY, et al. Prediction of recurrence and remission within 3 years in patients with Cushing disease after successful transnasal adenomectomy. Pituitary. 2019;22(6):574–580. DOI: 10.1007/s11102-019-00985-5.
21. Freddi G, Romàn-Pumar JL. Evidence-based medicine: what it can and cannot do. Ann Ist Super Sanita. 2011;47(1):22–25. DOI: 10.4415/ANN_11_01_06.
22. Meadows M. Genomics and personalized medicine. FDA Consum. November-December 2005;39(6):12–17.
23. Bunnik EM, Schermer MHN, Janssens AC. Personal genome testing: test characteristics to clarify the discourse on ethical, legal and societal issues. BMC Med Ethics. 2011;12:11. DOI: 10.1186/1472-6939-12-11.
24. Salari P, Larijani B. Ethical Issues Surrounding Personalized Medicine: A Literature Review. Acta Medica Iranica. 2017;55(3):209–217.
Review
For citations:
Mokrysheva N.G., Mel’nichenko G.A. Personalized medicine — stages of concept formation and ways of its practical implementation. Russian Journal for Personalized Medicine. 2021;1(1):43-58.
Views:
490
Email this article 